DEF: OneMedNet Schedules 2025 Annual Meeting, Board Elections

OneMedNet Corporation announced its 2025 Annual Meeting of Stockholders to be held virtually on December 17, 2025, to elect directors and ratify its independent accounting firm.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Wednesday, December 17, 2025, at 11:00 a.m. Central Time.
• Stockholders will vote on the election of two Class II directors, Robert Golden and Andrew Zeinfeld, to serve three-year terms expiring at the 2028 Annual Meeting.
• Stockholders will also vote to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2025.
• The record date for voting is October 23, 2025, with 51,157,069 shares of common stock issued and outstanding.
• Jair Clarke, a current director, will not stand for re-election, reducing the Board size to eight members after the Annual Meeting.
• The company dismissed its previous auditor, BF Borgers CPA PC, on May 6, 2024, following the SEC's permanent suspension of BF Borgers from practicing before the SEC.
• Material weaknesses in the company's internal control over financial reporting were identified for the year ended December 31, 2023.
• Significant related party transactions involving PIPE Notes, Convertible Promissory Notes, and Shareholder Loans with executive officers and directors (Aaron Green, Dr. Jeffrey Yu, Dr. Thomas Kosasa) were disclosed, totaling millions of dollars in financing and equity conversions.

Sentiment

Score: 3

Explanation: The filing details routine annual meeting proposals but also reveals significant negative issues such as the dismissal of a previously suspended auditor, identified material weaknesses in internal controls, and a high volume of related-party financing activities, which collectively indicate underlying operational and financial concerns.

Positives

• The Board recommends voting FOR the nominated Class II directors, Robert Golden and Andrew Zeinfeld, who bring extensive experience in accounting, finance, real estate, and senior management.
• The Board recommends voting FOR the ratification of WithumSmith+Brown, PC, demonstrating a commitment to good corporate governance by seeking stockholder approval for the auditor.
• The company adopted a compensation clawback policy in November 2024, aligning with evolving corporate governance best practices.
• The Annual Meeting will be held virtually, enhancing accessibility for stockholders and reducing the company's carbon footprint.

Negatives

• The company was required to dismiss its previous independent registered public accounting firm, BF Borgers CPA PC, due to a permanent suspension by the SEC.
• Material weaknesses in internal control over financial reporting were identified for the fiscal year ended December 31, 2023.
• Jair Clarke, a director with significant technology and AI experience (former Microsoft CTO, Disney, IBM), is not standing for re-election, which could result in a loss of valuable expertise on the Board.
• A high volume of related party transactions, including loans and equity conversions, with executive officers and directors raises potential concerns about conflicts of interest and transparency.

Risks

• Material weaknesses in internal control over financial reporting, as disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023, pose a risk to the integrity of financial reporting.
• Extensive related party transactions involving executive officers and directors could lead to perceived or actual conflicts of interest and impact investor confidence.
• The company's ability to continue as a going concern was noted in the prior auditor's report for the fiscal year ended December 31, 2023, indicating ongoing financial viability risks.
• The loss of a director with significant technology and AI expertise (Jair Clarke) could impact strategic direction and innovation.

Future Outlook

The filing primarily focuses on the procedural aspects of the upcoming annual meeting, including director elections and auditor ratification. It does not provide specific forward-looking financial guidance or strategic outlook beyond the terms of director service and the ongoing operations of the company.

Management Comments

• "We believe that holding the Annual Meeting virtually is an important step to enhancing accessibility to the meeting and reducing the carbon footprint of our activities." Dr. Jeffrey Yu, Chairman of the Board of Directors.
• "Our Board believes that our current leadership structure and the composition of our Board protect stockholder interests and provide adequate independent oversight, while also providing outstanding leadership and direction for our Board and management."

Industry Context

OneMedNet operates in the healthcare IT sector, with its Chief Medical Officer, Dr. Jeffrey Yu, having founded the concept of Legacy OneMedNet in 2015 to commercialize the BEAM solution for imaging specialists. The company's executive team includes leaders with extensive experience in healthcare management, sales, strategic planning, and M&A within healthcare technology. The involvement of directors like Dr. Kenneth Alleyne, who co-founded Fizio Health (an AI-powered computer vision technology for remote physical therapy), indicates an alignment with broader industry trends towards digital transformation and AI integration in healthcare.

Comparison to Industry Standards

• The dismissal of BF Borgers CPA PC due to an SEC permanent suspension underscores the critical importance of selecting and overseeing independent auditors, a fundamental aspect of corporate governance and regulatory compliance for all publicly traded companies.
• The adoption of a compensation clawback policy in November 2024 aligns OneMedNet with evolving corporate governance standards, particularly those influenced by the Dodd-Frank Act and subsequent SEC rules, which aim to enhance accountability for executive compensation.
• The decision to hold the Annual Meeting virtually is consistent with a growing trend among public companies to leverage technology for increased stockholder accessibility and to reduce operational costs and environmental impact, reflecting modern corporate practices.
• The disclosure of material weaknesses in internal control over financial reporting for 2023 indicates a deviation from best practices in financial controls, which are standard for public companies to ensure accurate and reliable financial reporting.

Management Changes

Corporate Governance

Related Party Transactions

• Related party investors, including Mr. Green, Dr. Yu, and Dr. Kosasa, contributed $1.0 million to PIPE Notes out of a total of $1.5 million, and received 63,829 PIPE Warrants.
• Related party investors contributed $12.3 million to Convertible Promissory Notes out of a total of $14.2 million, and received 2,976,000 Convertible Promissory Note Warrants.
• Dr. Yu and Dr. Kosasa provided $954 thousand in Shareholder Loans to the company from April to December 2023.
• Dr. Yu and Dr. Kosasa provided $2.0 million in Shareholder Loans to the company during 2024, with $1.6 million being convertible into common stock.
• The company assumed $3.0 million in loan extensions to related parties from Data Knights liabilities, which remained outstanding as of December 31, 2024.
• On June 19, 2025, Dr. Kosasa and Dr. Yu converted approximately $3.3 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans into 4,693,296 shares of Common Stock at $0.71 per share.
• On June 19, 2025, Dr. Kosasa converted approximately $1.6 million of convertible shareholder loans into 2,123,424 shares of Common Stock at $0.7535 per share.
• On June 20, 2025, Dr. Kosasa invested $500,000 for 1,190,476 shares of Common Stock at $0.42 per share.
• On June 20, 2025, Dr. Yu invested $700,000 for 1,666,666 shares of Common Stock at $0.42 per share.
• On August 29, 2025, Dr. Kosasa invested $500,000 for 581,395 shares of Common Stock at $0.86 per share.

Stakeholder Impact

• **Shareholders**: Will participate in corporate governance by voting on director elections and auditor ratification. They are directly impacted by the company's financial health, internal control weaknesses, and potential dilution from extensive related-party equity conversions.
• **Employees**: Executive compensation details are provided, and the adoption of a clawback policy affects current and former executive officers, promoting accountability.
• **Creditors**: The significant volume of related-party loans and their subsequent conversion to equity could impact the company's capital structure and risk profile from a creditor's perspective.
• **Regulatory Authorities**: The dismissal of the previous auditor due to SEC suspension highlights the company's interaction with regulatory bodies and the importance of compliance with SEC rules regarding financial reporting and auditing.

Next Steps

• Stockholders are encouraged to review proxy materials and vote on the election of Class II directors and the ratification of the independent registered public accounting firm prior to or during the Annual Meeting on December 17, 2025.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days following the meeting.
• If stockholders do not ratify the appointment of WithumSmith+Brown, PC, the Audit Committee will investigate the reasons and reconsider the appointment.
• Jair Clarke will continue to serve the company in an advisory capacity after the expiration of his director term at the Annual Meeting.

Key Dates

Recommendation

The filing reveals significant red flags for investors, including the dismissal of a previously suspended auditor, acknowledged material weaknesses in internal controls over financial reporting, and a high volume of related-party financing activities involving executive officers and directors. These issues collectively point to potential governance and financial integrity concerns, suggesting a higher risk profile for the company. The continuous reliance on related-party financing and equity conversions at varying prices could lead to further dilution and raise questions about the company's ability to secure independent funding, making the stock a 'sell' for a seasoned investor.

Keywords

OneMedNet, OMN, Proxy Statement, Annual Meeting, Corporate Governance, Board of Directors, Director Election, Auditor Ratification, SEC Filing, DEF 14A, Financial Reporting, Internal Controls, Related Party Transactions, Executive Compensation, Healthcare IT